Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Tumor-Agnostic 2Thoracic 2NET 2Endocrine 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 3Neoplasms 2Stomach Neoplasms 1Sarcoma 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenoma, Islet Cell 1

Interventions

Everolimus 5Sunitinib 4lutetium Lu 177 dotatate 2PM 01183 2Octreotide 2Doxorubicin 2trifluridine tipiracil drug combination 1telotristat ethyl 1repotrectinib 1pralsetinib 1pegfilgrastim 1pasireotide 1motesanib diphosphate 1epothilone B 1dactolisib 1copper dotatate CU-64 1batifiban 1avelumab 1alectinib 1Temozolomide 1TKM-080301 1Surveys and Questionnaires 1SNX-5422 1Referral and Consultation 1Radiomics 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × PM 01183 × NET × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡